10/9/2013

Bayer obtained the FDA's approval to market Adempas, or riociguat, as a treatment for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension. The drug will be sold with a boxed warning on its label against use by pregnant women because of potential harms to prenatal development.

Related Summaries